It's interesting to see Novogen didn't make an announcement even though some very market sensitive news was released.
I would have thought that mentioning the 20-30% success rate (which is great in such sick patients) and the fact that more trials are about to start, and that they have found a new compound on pancreatic cancer is all market sensitive?
I'm sure most NRT owners don't know any of this and might infact have a sell order in the market just because they don't know that the drug works yet.
From Dr Rutherford's (Yale university) mouth... "that's phenomenal" when referring to the 20-30% success rate.
Cheers, Munch.
NRT Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held